Business Description
Penumbra Inc
NAICS : 339999
SIC : 3841
ISIN : US70975L1070
Total Employee Number:
4,700Description
Domiciled in the US, Penumbra designs, manufactures, and markets an array of thrombectomy and embolization devices and equipment to mechanically remove blood clots. The firm sells mainly to hospitals and physicians. These minimally invasive devices are primarily used in the acute care setting for patients with stroke, pulmonary embolism, deep vein thrombosis, cranial aneurysms, and other vascular diseases.
Financial Strength
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 3.1 | |||||
Equity-to-Asset | 0.78 | |||||
Debt-to-Equity | 0.14 | |||||
Debt-to-EBITDA | 0.96 | |||||
Interest Coverage | 144.22 | |||||
Piotroski F-Score | 6/9 | |||||
Altman Z-Score | 19.15 | |||||
Beneish M-Score | -2.75 | |||||
WACC vs ROIC | ||||||
Growth Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 16.9 | |||||
3-Year EBITDA Growth Rate | 93.1 | |||||
3-Year EPS without NRI Growth Rate | 188.4 | |||||
3-Year Book Growth Rate | 11.6 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 24.45 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 13.14 |
Momentum Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 45.06 | |||||
9-Day RSI | 45.29 | |||||
14-Day RSI | 47.6 | |||||
3-1 Month Momentum % | 1.12 | |||||
6-1 Month Momentum % | -4.53 | |||||
12-1 Month Momentum % | 15.91 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 5.75 | |||||
Quick Ratio | 3.86 | |||||
Cash Ratio | 2.82 | |||||
Days Inventory | 327.72 | |||||
Days Sales Outstanding | 44.76 | |||||
Days Payable | 27.31 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -1 | |||||
Shareholder Yield % | 0.05 |
Profitability Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 67.84 | |||||
Operating Margin % | 12.45 | |||||
Net Margin % | 10.67 | |||||
EBITDA Margin % | 14.77 | |||||
FCF Margin % | 14.35 | |||||
OCF Margin % | 18.46 | |||||
ROE % | 11.33 | |||||
ROA % | 8.81 | |||||
ROIC % | 13.35 | |||||
ROC (Joel Greenblatt) % | 25.52 | |||||
ROCE % | 12.56 | |||||
Years of Profitability over Past 10-Year | 8 | |||||
Moat Score | 6 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 79.16 | |||||
Forward PE Ratio | 51.87 | |||||
PE Ratio without NRI | 79.55 | |||||
Shiller PE Ratio | 284.52 | |||||
Price-to-Owner-Earnings | 66.3 | |||||
PS Ratio | 8.45 | |||||
PB Ratio | 8.29 | |||||
Price-to-Tangible-Book | 9.34 | |||||
Price-to-Free-Cash-Flow | 58.88 | |||||
Price-to-Operating-Cash-Flow | 45.76 | |||||
EV-to-EBIT | 59.69 | |||||
EV-to-Forward-EBIT | 45.01 | |||||
EV-to-EBITDA | 55.09 | |||||
EV-to-Forward-EBITDA | 42.17 | |||||
EV-to-Revenue | 8.14 | |||||
EV-to-Forward-Revenue | 6.76 | |||||
EV-to-FCF | 56.71 | |||||
Price-to-GF-Value | 0.96 | |||||
Price-to-Projected-FCF | 6.03 | |||||
Price-to-Median-PS-Value | 0.8 | |||||
Price-to-Graham-Number | 5.75 | |||||
| Price-to-Net-Current-Asset-Value | 14.1 | |||||
| Price-to-Net-Cash | 59.11 | |||||
Earnings Yield (Greenblatt) % | 1.68 | |||||
FCF Yield % | 1.7 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NYSE:PEN
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Penumbra Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 1,504.874 | ||
| EPS (TTM) ($) | 4.07 | ||
| Beta | 0.4428 | ||
| 3-Year Sharpe Ratio | 0.23 | ||
| 3-Year Sortino Ratio | 0.41 | ||
| Volatility % | 37.13 | ||
| 14-Day RSI | 47.6 | ||
| 14-Day ATR ($) | 2.210125 | ||
| 20-Day SMA ($) | 324.2975 | ||
| 12-1 Month Momentum % | 15.91 | ||
| 52-Week Range ($) | 221.26 - 362.41 | ||
| Shares Outstanding (Mil) | 39.39 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Penumbra Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Penumbra Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Annual report for 2026 | 2027-02-25 | In 172 days | ||
| Fourth quarter earnings results for 2026 | 2027-02-25 | In 172 days | ||
| Third quarter earnings conference call for 2026 | 2026-11-05 16:30 | In 61 days | ||
| Third quarter earnings results for 2026 | 2026-11-05 | In 60 days | ||
| Second quarter earnings results for 2026 | 2026-07-30 | 320.13 (+0.51%) | ||
| General meeting for 2026 | 2026-06-18 11:00 | 316.16 (-0.58%) | ||
| First quarter earnings results for 2026 | 2026-05-06 | 323.86 (-0.37%) | ||
| Annual report for 2025 | 2026-02-25 | 339.59 (+0.01%) | ||
| Fourth quarter earnings results for 2025 | 2026-02-25 | 339.59 (+0.01%) | ||
| 44th Annual J.P. Morgan Healthcare Conference | 2026-01-12 18:45 | 322.44 (+1.59%) |
Show
Entries
Penumbra Inc Frequently Asked Questions
What is Penumbra Inc(PEN)'s stock price today?
The current price of PEN is $322.17. The 52 week high of PEN is $362.41 and 52 week low is $221.26.
When is next earnings date of Penumbra Inc(PEN)?
The next earnings date of Penumbra Inc(PEN) is 2026-11-05 Est..
Does Penumbra Inc(PEN) pay dividends? If so, how much?
Penumbra Inc(PEN) does not pay dividend.
Guru Commentaries on NYSE:PEN
Artisan Partners Small Cap Fund
Bearish
2026 Q1
What the manager wrote
We ended our investment campaigns in Penumbra... The acquisition validated our investment thesis and provided an attractive opportunity to take profits. We had been building the position throughout 2025 as adoption of Penumbra’s core product portfolio expanded and clinical momentum improved across key indications.
2025 Q1
What the manager wrote
Penumbra was one of our medical technology holdings that made positive contributions to relative performance, particularly following favorable stock reactions to quarterly earnings and calendar 2025 guidance. Despite some shorter-term headwinds in the healthcare sector, we believe that the resulting volatility can yield opportunities for favorable long-term returns when quality science and care meet societal health needs.
NCG SMID Cap Growth Strategy
Neutral
2025 Q1
What the manager wrote
The manager added Penumbra, Inc. to the portfolio in Q1 2025, indicating a focus on investing in companies with strong business fundamentals and that can sustain high growth. However, there is no explicit directional argument made about the future performance or valuation of Penumbra, Inc.
Press Release
Articles on Penumbra Inc
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers